


This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Translation Arrest by RNase h Incompetent Antisense Oligonucleotides

I. Robbins^a; J. E. Gee^a; G. Mitta^a; B. Rayner^b; S. Vichier-guerre^b; M. Leng^c; A. van der Laan^d; J. van Boom^d; J. S. Nelson^c; B. Lebleu^a

^a Institut de Génétique Moléculaire, CNRS, Montpellier, France ^b Laboratoire de Chimie Bio-organique, CNRS Université de Montpellier 2, Montpellier, France ^c Centre de Biophysique Moléculaire, CNRS, Orléans, France ^d Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands ^e Lynx Therapeutics, Hayward, CA, USA

To cite this Article Robbins, I. , Gee, J. E. , Mitta, G. , Rayner, B. , Vichier-guerre, S. , Leng, M. , van der Laan, A. , van Boom, J. , Nelson, J. S. and Lebleu, B.(1999) 'Translation Arrest by RNase h Incompetent Antisense Oligonucleotides', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 6, 1667 — 1668

To link to this Article: DOI: 10.1080/07328319908044817

URL: <http://dx.doi.org/10.1080/07328319908044817>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

TRANSLATION ARREST BY RNase H INCOMPETENT ANTISENSE OLIGONUCLEOTIDES

I. Robbins, J.E. Gee, G. Mitta, B. Rayner^a, S. Vichier-Guerre^a, M. Leng^b, A. Van der Laan^c, J. van Boom^c, J. S. Nelson^d, and B. Lebleu^{*}

Institut de Génétique Moléculaire, CNRS, Montpellier, France; ^aLaboratoire de Chimie Bio-organique, CNRS Université de Montpellier 2, Montpellier, France; ^bCentre de Biophysique Moléculaire, CNRS, Orléans, France; ^cLeiden Institute of Chemistry, Leiden University, Leiden, Netherlands; ^dLynx Therapeutics, Hayward, CA 94545, USA

ABSTRACT: Most second-generation ON antisense analogs do not activate RNase H. Alternative strategies to arrest translation in a reticulocyte cell-free assay programmed by VSV mRNAs have been explored.

Activation of RNase H by antisense oligonucleotides (ON) is generally accepted to be the most efficient strategy to interfere with mRNA translation. Many ON analogs, *e.g.* alpha-anomeric analogs, or peptide nucleic acids, possess interesting pharmacological properties, but are incapable of activating RNase H. We have assessed the extent with which high-affinity hybridization, covalent linkage and activation of alternative degradative pathways can be used to arrest translation elongation, using a reticulocyte lysate programmed with vesicular stomatitis virus (VSV) mRNA^{1,2}.

Phosphodiester ON targeted to various portions of the VSV N protein mRNA coding region specifically arrest translation in the presence of exogenous *E. coli* RNase H, leading to the accumulation of truncated peptides. RNase H-incompetent ON are unable to block translation in this assay, despite their high affinity *e.g.* a T_m superior to 70° C for N 3' phosphoramidates or PNAs³. Mixed-backbone antisense ON comprising a central phosphodiester window (to activate RNase H) and modified arms (to provide nuclease resistance and improved affinity for the target) represent an interesting

compromise. New methods for the synthesis of PNA-DNA chimeras⁴ have allowed the implementation of this strategy to PNAs. Preliminary experiments have indicated that certain PNA-DNA chimeras possess the capacity to activate RNase H and as a consequence lead to *in vitro* translation inhibition (Robbins *et al* in preparation). However, PNA-RNA duplexes have unusual helical structures⁵ creating distortions. This may account for the low T_m of these chimeras with respect to their PNA content and might limit the application of this strategy.

Steric hindrance through covalent attachment *via* a trans-platin modified antisense ON⁶ has allowed a specific and RNase H-independent blockade of VSV N protein synthesis at doses as low as 10nM, *e.g.* at nearly stoichiometric ratios³.

Alternatively alpha-anomeric ON analogues can be converted into sequence-specific nucleases upon conjugation to 2-5A oligomers. However, target selection appears critical to promote the assembly of the appropriate ternary complex between the mRNA target, the antisense ON 2-5A chimera and the RNase L effector⁷.

REFERENCES

1. Degols, G.; Leonetti, J.P.; Gagnor, C.; Lemaitre, M.; Lebleu, B. *Nucl. Acids Res.* **1989**, *22*, 9341-9350.
2. Robbins, I.; Lebleu, B. *Methodes in Enzymology*, in press.
3. Gee, J.E.; Robbins, I.; Van der Laan, A.C.; van Boom, J.H.; Colombier, C.; Leng, M.; Raible, A.M.; Nelson, J.S.; Lebleu, B. *Antisense Nucl. Acid Drug Develop.* **1998**, *8*, 103-111.
4. Van der Laan, A.C.; Brill, R.; Kuimelis, R.; Kuyl-Yeheskiely, E.; van Boom, J.H.; Andrus, A.; Vinayak, R. *Tetrahedron Lett.* **1997**, *38*, 2249-2252.
5. Nielsen, P.E.; Haima, G. *Chem. Soc. Rev.* **1997**, 73-78.
6. Colombier, C.; Boudvillain, M.; Leng, M. *Antisense Nucl. Acid Drug Develop.* **1997**, *7*, 397-402.
7. Robbins, I.; Mitta, G.; Vichier-Guerre, S.; Sobol, R.; Ubysz, A.; Rayner, B.; Lebleu, B. *Biochimie*, **1998**, *80*, 1-10.